查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844086

按治疗类型、给药途径、最终用户和骨折类型分類的骨质疏鬆症和骨折治疗市场—2025-2032年全球预测

Anti-Osteoporosis Therapy & Fracture Healing Market by Therapy Type, Route Of Administration, End User, Fracture Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，骨质疏鬆症和骨折治疗市场将成长至 293.5 亿美元，复合年增长率为 8.78%。

主要市场统计数据
基准年 2024 149.7亿美元
预计年份：2025年 162.8亿美元
预测年份：2032年 293.5亿美元
复合年增长率 (%) 8.78%

简明框架阐述了影响骨质疏鬆症和骨折治疗领域的临床重点、治疗方法进展和医疗服务模式动态。

骨质疏鬆症和骨折治疗在老龄化社会的医疗保健策略和全球治疗创新议程中占据核心地位。随着人口结构变化导致高风险族群不断扩大，临床路径、支付方期望和医疗服务模式也在同步演变。这种互动将影响临床医生、医院系统、支付方和製造商决策的临床需求和商业性现实结合起来。

目前，低骨量和脆性骨折的治疗依赖于药物、器械干预以及以二级预防为重点的协调护理体系的协同作用。同时，长期治疗依从性、给药途径偏好以及新型生技药品的出现正在重塑治疗流程。监管核准、安全性资讯和真实世界证据正在以因地区而异的方式影响製剂研发者的信心和配製实践。

在此背景下，相关人员必须权衡临床疗效与营运可行性，并认识到成功的骨折预防和治疗方案需要基层医疗、专科诊所、医院和居家照护服务之间的整合。这项认知为策略性地解读以下章节奠定了基础，这些章节将分析产业转型、贸易政策影响、市场区隔资讯、区域动态、竞争对手活动，并为希望将洞察转化为行动的领导者提供切实可行的建议。

生技药品、以病人为中心的给药方案、精准治疗管道以及供应弹性如何重塑治疗策略和商业模式

骨质疏鬆症和骨折治疗的治疗格局和竞争格局正经历多重加速的同步转变，这些转变正在改变临床和竞争定位。首先，单株抗体疗法和合成代谢药物的成熟正在将治疗顺序转向快速降低骨折风险和促进骨骼生长的策略，促使临床医生重新审视他们长期以来对单药抗骨吸收疗法的依赖。

其次，以病人为中心的照护模式和注重依从性的医疗器材创新正在提升给药途径和给药便利性的重要性。与每日或每週口服疗法相比，剂量精准的注射疗法正在改变患者的依从性，这种变化促使支付方和医疗服务提供者重新思考护理路径和支持服务。第三，精准医疗和数位健康的整合正在实现更精细的风险分层，影像生物标记和综合骨折联络服务有助于提高病例检出率和及时干预能力。

最后，供应链韧性和生物相似药的竞争正成为商业规划中的策略变数。製造商正透过多元化产品组合、对已上市药物进行生命週期管理以及加速整合临床服务、诊断和患者支持的伙伴关係来适应这些变化。虽然这些变革性转变增加了商业化的复杂性，但也创造了在临床效益和营运可扩展性之间取得平衡的差异化路径。

评估2025年关税调整对骨质疏鬆症医疗保健供应链、采购和治疗取得的营运和策略影响。

2025年关税调整和贸易政策变更的实施，为骨质疏鬆症和骨折治疗产品相关相关人员带来了新的成本和供应方面的考量。对药品原料和成品征收关税可能会增加到岸成本，尤其是对于复杂的生技药品原料和某些依赖国际采购的专用成分的治疗层级。这反过来又会影响医院系统和专科诊所的价格谈判、筹资策略和库存管理决策。

製造商和经销商正在透过重新评估其全球製造地、加大近岸外包投资以及加快替代原料药和辅料供应商的资质认证来应对，以确保供应的连续性。同时，支付者和综合医疗系统正在加强对成本效益的审查，并可能优先考虑供应链稳定、成本结构透明的治疗方案。这些趋势既带来了挑战，也带来了机会。虽然关税会造成短期利润压力和采购复杂性，但它们也会促使企业投资于具有韧性的生产、垂直整合以及策略供应商联盟，从而降低未来贸易中断的风险。

此外，监管机构和海关部门越来越重视文件记录和可追溯性，这就要求品质、法规和商业团队之间加强合作。对于创新者和现有产品所有者而言，积极规划供应链方案并与采购相关人员合作至关重要，这有助于减轻关税调整带来的累积营运影响，并确保临床医生和患者能够获得关键治疗方法。

分析治疗层级、给药途径、治疗环境和骨折特定需求，以使临床证据与商业性策略一致，从而提高产品普及率。

解读市场区隔的细微差别，可以揭示临床需求、商业机会和营运摩擦的交汇点，而将这些细分市场的特征转化为可执行的策略至关重要。治疗方法类型涵盖了从经典的抗骨吸收药物（例如双磷酸盐）到阿崙膦酸钠、Ibandronate sodium、利塞膦酸钠和Zoledronic acid等药物。荷尔蒙补充疗法包括联合治疗和以雌激素为重点的治疗策略。单株抗体疗法包括Denosumab和Denosumab，其商品名分别为Prolia和Xgeva。副甲状腺素类似物包括阿巴洛帕肽和特立帕肽。选择性雌激素受体调节（例如Bazedoxifene和Raloxifene）在特定患者群体中继续占据一定的市场地位。这些治疗方法的差异性取决于疗效、安全性、患者合併症和製剂定位等因素，进而推动临床应用。

在考虑给药途径时，注射和口服途径必须权衡患者的便利性、对顺从性的影响以及医疗服务能力。可用于静脉或皮下注射的注射剂通常需要医疗机构资源或经过培训的居家照护服务，而门诊病人，但面临依从性方面的挑战。就最终用户而言，服务提供场所包括居家医疗机构、医院和专科诊所，每种场所都有其独特的采购、管理和报销动态，这些都会影响产品选择和支援需求。对骨折类型进行细分，可以揭示临床优先领域——髋部、脊柱和手腕关节骨折——这些领域在患病率、急性护理需求和復健途径方面的差异反映了治疗的紧迫性和二级预防策略。这种综合细分有助于产生有针对性的临床证据、客製化患者支援计画以及製定针对特定管道的商业策略，从而优化患者的接受度和治疗效果。

美洲、欧洲、中东和非洲以及亚太地区在监管、报销和供应方面的差异将决定其准入和推广管道。

区域动态持续影响骨质疏鬆症治疗和骨折管理方案的取得、报销和临床应用模式。在美洲，整合式医疗服务体系、以支付方主导的配药流程，以及日益重视与骨折和再入院率等结果挂钩的价值导向型合同，都在影响着市场需求。这些压力促使生产者展示产品在实际应用中的有效性，并与医疗系统合作进行上市后实证研究和病患支援计画。

在欧洲、中东和非洲，监管协调、国家采购框架和不同的报销环境造就了多种多样的市场参与策略。各国在价格谈判机制和卫生技术评估方法上的差异，使得市场准入计画和针对特定临床和经济终点的本地证据变得至关重要。该地区也为进行深入的临床合作和区域製造投资提供了机会，从而提高了供应安全。

亚太地区的市场发展轨迹各不相同，有的高所得都市区正迅速扩大先进生技药品的可近性，有的新兴市场则不断提升基层医疗能力。部分市场的地方监管趋势、临床试验的活性化以及对诊断基础设施投资的加大，正在推动创新药物的快速普及，而成本和物流问题则在其他市场构成重大障碍。在所有地区，最佳实践的骨折联络服务和跨境远端医疗监测合作正成为提升病患疗效和扩大治疗覆盖范围的关键因素。

竞争策略的核心是提供生技药品创新、生命週期管理、伙伴关係和整合服务，从而塑造产品发展轨迹。

在骨质疏鬆症和骨折治疗领域，各公司的策略涵盖多种途径，从产品组合多元化和生物创新到生命週期管理和服务整合。一些领先的创新企业正专注于单株抗体和合成代谢剂平台的开发，利用差异化的临床特征来确保製剂优势并获得专家的认可。这些公司正大力投资长期安全性监测、头对头试验和大规模观察性研究，以维持临床医生的信心并影响指南的发展。

同时，拥有成熟小分子药物组合的公司正优先考虑成本控制策略、生产优化以及能够提高患者依从性的患者支援服务。随着各公司致力于为骨折预防和治疗提供一站式解决方案，诊断服务提供者、居家照护业者和数位医疗公司之间的合作日益普遍。生物相似药的参与企业和契约製造生产商正在影响定价动态和供应灵活性，迫使原厂药企业加快创新步伐，并探索新的商业模式，例如基于疗效的定价模式。

从竞争格局来看，智慧财产权管理、监理生命週期规划和地域性生产多元化是反覆出现的主题。那些拥有强有力的临床证据、稳健的供应链和一体化服务产品的公司，更有利于保持竞争力；而那些未能适应不断变化的支付方要求和患者期望的公司，则面临在关键通路市场份额下降的风险。

以实证实践、供应链韧性、以患者为中心的医疗服务以及新型商业模式为重点，采取切实可行的策略倡议，以确保竞争优势。

产业领导者应采取一系列协调一致的策略行动，使临床差异化与营运韧性以及支付方的期望一致。首先，应优先产生真实世界证据和比较疗效数据，以证明其临床效用和系统价值，从而增强与支付方的谈判能力，并使其能够纳入以指南为导向的诊疗路径。其次，应投资于供应链多元化和近岸外包，以降低关税和贸易中断带来的风险，同时透过资格确认流程确保品质和合规性。

第三，我们将设计以病人为中心的支持计画和给药途径，结合口服药物的便利性和注射疗法的依从性优势。第四，我们将与诊断机构和骨折联络服务机构进行策略合作，以优化病例发现和二级预防流程。第五，我们将探索适应性商业模式，例如骨折治疗的风险分担协议和打包支付，以协调各相关人员的奖励。

最后，在产品开发和生命週期活动的早期阶段就纳入监管和卫生技术评估计划，可以加快产品上市速度，并主动满足支付方的证据要求。透过协调临床、营运和商业方面的优先事项，企业领导者可以将新兴趋势转化为可持续的竞争优势。

一种综合性的、经过同侪检验的研究途径，结合了第一手资料和第二手资料。

本分析的调查方法整合了多种证据来源、同行检验和迭代三角测量，以得​​出可操作的见解。主要研究包括与内分泌科和整形外科临床专家、医院药房主任、专科诊所经理以及支付方和采购代表进行结构化访谈和咨询讨论，从而获得关于配药行为、配药决策和医疗服务限制的第一手观点。

二次研究包括对监管核准、同行评审的临床文献、指南声明、产品标籤和公开的安全资讯进行系统性回顾，以确认其与近期临床和监管进展的一致性。此外，还查阅了真实世界资讯来源，例如医疗资源利用报告、临床註册研究和已发表的结局研究，以阐明治疗结果和上市后经验。

资料综合依赖于原始研究结果和二手资料集的交叉验证，并采用主题编码来识别反覆出现的机会和风险。情境分析和敏感性测试用于评估供应链和贸易政策变化对营运的影响。在整个研究过程中，品质保证通讯协定确保了资料来源的可追溯性和一致性，专家对研究结果草稿进行了审查，以确保其临床和商业性相关性。

将治疗方法创新、服务模式转型和营运韧性联繫起来的集体智慧，为在骨折预防和治疗方面产生持久影响指明了清晰方向。

总之，骨质疏鬆症和骨折的治疗格局正处于曲折点，其驱动力包括治疗创新、不断演变的医疗服务模式以及新的供应链和贸易考量。合成代谢类固醇和单株抗体动态的兴起正在重塑临床决策，而用药依从性和给药途径的动态变化则持续影响实际疗效。同时，关税以及支付方日益关注治疗结果等因素也正在重塑商业化策略和产业计画。

积极整合可靠的证据生成、灵活的生产和筹资策略以及以患者为中心的服务模式的利益相关人员，将更有能力应对这一复杂的环境。连结诊断、数位健康和​​护理协调服务的跨部门合作，有望提高病例检出率并减轻后续骨折负担。最终，那些将科学差异化、可验证的价值以及医疗保健系统稳健运作相结合的机构，将在成熟市场和新兴市场中获得持久的机会。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 罗莫索单抗疗法的进展正受到严格审查，以评估其对高风险骨质疏鬆症患者的心血管安全性。
  • 整合穿戴式感测器和人工智慧演算法，即时监测骨癒合进展
  • 利用基因治疗方法标靶成骨细胞活性，促进骨质疏鬆症患者骨折修復的新方法
  • 开发新型硬骨素抑制剂，以提高骨再生疗效并减少脱靶不利事件
  • 单株抗体和双磷酸盐联合治疗在治疗重度骨质疏鬆症的应用日益广泛
  • 扩展家庭远端医疗平台，用于远端监测骨骼密度和骨折治疗效果
  • 用于长期治疗骨质疏鬆症的合成代谢药物的监管核准影响市场进入策略。
  • 研究调节肠道菌丛对提高骨骼密度和降低骨折风险的影响

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 依治疗类型分類的骨质疏鬆症和骨折治疗市场

  • 双磷酸盐
    • 阿崙膦酸钠
    • Ibandronate sodium
    • 利塞膦酸钠
    • Zoledronic acid
  • 荷尔蒙补充疗法
    • 联合荷尔蒙疗法
    • 雌激素疗法
  • 单株抗体
    • Denosumab
      • 普罗利亚
      • XGEVA
    • 罗莫索单抗
  • 副甲状腺素类似物
    • 阿巴洛帕拉肽
    • 特立帕肽
  • 选择性雌激素受体调节
    • Bazedoxifene
    • Raloxifene

9. 依给药途径分類的骨质疏鬆症和骨折治疗市场

  • 注射
    • 静脉
    • 皮下
  • 口服

第十章 依最终使用者分類的骨质疏鬆症和骨折治疗市场

  • 居家医疗
  • 医院
  • 专科诊所

第十一章 依骨折类型分類的骨质疏鬆症和骨折治疗市场

  • 腰部
  • 脊椎
  • 手腕

12. 各地区骨质疏鬆症及骨折治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 按组别分類的骨质疏鬆症和骨折治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国骨质疏鬆症及骨折治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Amgen Inc.
    • Stryker Corporation
    • Medtronic plc
    • Novartis AG
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • Orthofix Medical Inc.
Product Code: MRR-CA17E905EAC5

The Anti-Osteoporosis Therapy & Fracture Healing Market is projected to grow by USD 29.35 billion at a CAGR of 8.78% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 14.97 billion
Estimated Year [2025] USD 16.28 billion
Forecast Year [2032] USD 29.35 billion
CAGR (%) 8.78%

A concise framing of clinical priorities, therapeutic evolution, and delivery model dynamics shaping anti-osteoporosis care and fracture healing pathways

Osteoporosis and fracture healing occupy a central position in aging-population healthcare strategies and in therapeutic innovation agendas worldwide. As demographic shifts continue to expand the population at risk, clinical pathways, payer expectations, and delivery models are evolving concurrently. This introduction frames the clinical imperatives and commercial realities that shape decisions by clinicians, hospital systems, payers, and manufacturers.

Contemporary management of low bone mass and fragility fractures relies on an interplay of pharmacologic agents, device-facilitated interventions, and coordinated care pathways that prioritize secondary prevention. In parallel, longer-term therapy adherence, route-of-administration preferences, and the emergence of novel biologics are reshaping treatment algorithms. Regulatory approvals, safety communications, and real-world evidence are influencing prescriber confidence and formulary placement in distinct ways across regions.

Against this backdrop, stakeholders must balance clinical efficacy with operational feasibility, recognizing that successful fracture prevention and healing programs demand integration across primary care, specialty clinics, hospitals, and homecare services. This introduction sets the stage for a strategic reading of subsequent sections that analyze transformative industry shifts, trade policy impacts, segmentation intelligence, regional dynamics, competitor activity, and pragmatic recommendations for leaders aiming to convert insight into action.

How biologics, patient-centric administration, precision care pathways, and supply resilience are remapping therapeutic strategies and commercial models

The therapeutic and commercial landscape for osteoporosis and fracture healing is undergoing several concurrently accelerating shifts that are transforming clinical practice and competitive positioning. First, the maturation of monoclonal antibody therapeutics and anabolic agents has redirected treatment sequencing conversations toward rapid fracture risk reduction and bone formation strategies, prompting clinicians to reassess long-standing reliance on antiresorptives alone.

Second, patient-centric care models and adherence-aware device innovations are elevating the importance of route of administration and dosing convenience. Injectable regimens that offer infrequent dosing intervals are changing adherence profiles relative to daily or weekly oral therapies, and this dynamic is prompting payers and providers to reconsider care pathways and support services. Third, the intersection of precision medicine and digital health is enabling more granular risk stratification, with imaging biomarkers and integrated fracture liaison services improving case-finding and timely intervention.

Finally, supply chain resilience and biosimilar competition are emerging as strategic variables in commercial planning. Manufacturers are adapting by diversifying portfolios, pursuing lifecycle management for established agents, and accelerating partnerships that integrate clinical services, diagnostics, and patient support. These transformative shifts are collectively increasing the complexity of commercialization while creating differentiated pathways for organizations that align clinical benefit with operational scalability.

Evaluating the operational and strategic consequences of 2025 tariff adjustments on supply chains, procurement, and therapeutic access across osteoporosis care

The introduction of tariff changes and trade policy adjustments in 2025 has introduced novel cost and supply considerations for stakeholders involved in anti-osteoporosis therapies and fracture-healing products. Tariffs on pharmaceutical inputs and finished goods can increase landed costs for certain therapeutic classes, particularly those with complex biologic manufacturing inputs or reliance on specialized components sourced internationally. This, in turn, affects pricing negotiations, procurement strategies, and inventory management decisions across hospital systems and specialty clinics.

Manufacturers and distributors are responding by re-evaluating global manufacturing footprints, increasing nearshoring investments, and accelerating qualification of alternative API and component suppliers to preserve continuity of supply. In parallel, payers and integrated health systems are intensifying scrutiny of cost-effectiveness and may prioritize therapies with stable supply chains and transparent cost structures. These trends create both headwinds and opportunities: while tariffs introduce short-term margin pressure and procurement complexity, they also incentivize investments in resilient manufacturing, vertical integration, and strategic supplier alliances that can reduce exposure to future trade disruptions.

Moreover, regulatory agencies and customs authorities are placing greater emphasis on documentation and traceability, which requires enhanced coordination between quality, regulatory affairs, and commercial teams. For innovators and established product owners alike, proactive supply chain scenario planning and engagement with procurement stakeholders will be essential to mitigate the cumulative operational impact of tariff shifts and to maintain clinician and patient access to critical therapies.

Dissecting therapy classes, administration routes, care settings, and fracture-specific needs to align clinical evidence and commercial tactics for better adoption

A nuanced reading of market segmentation illuminates where clinical needs, commercial opportunity, and operational friction converge, and it is essential to translate those segment-level characteristics into actionable tactics. Based on therapy type, the landscape spans classic antiresorptives such as bisphosphonates, which are further differentiated into agents like alendronate, ibandronate, risedronate, and zoledronic acid, alongside hormone replacement therapies that include combined hormone options and estrogen-focused strategies. Monoclonal antibody treatments are represented by denosumab and romosozumab, with denosumab delivered under branded indications such as Prolia and Xgeva, while parathyroid hormone analogues include abaloparatide and teriparatide. Selective estrogen receptor modulators such as bazedoxifene and raloxifene continue to occupy niche positions in specific patient cohorts. These therapy distinctions drive differential clinical adoption based on efficacy profiles, safety considerations, patient comorbidities, and formulary positioning.

When considering route of administration, injectable and oral pathways must be weighed against patient convenience, adherence implications, and healthcare delivery capacity; injectable options that can be administered intravenously or subcutaneously often require facility-based resources or trained homecare services, whereas oral agents offer outpatient convenience but face adherence challenges. Examining end users, service delivery occurs across homecare environments, hospitals, and specialty clinics, each with unique procurement, administration, and reimbursement dynamics that influence product selection and support requirements. Fracture type segmentation highlights clinical priority areas-hip, spinal, and wrist fractures-where differences in morbidity, acute care needs, and rehabilitation pathways inform therapeutic urgency and secondary prevention strategies. Taken together, these segmentation lenses should inform targeted clinical evidence generation, tailored patient support programs, and channel-specific commercial tactics to optimize uptake and patient outcomes.

Regional regulatory, reimbursement, and delivery contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access and adoption pathways

Regional dynamics continue to shape access, reimbursement, and clinical adoption patterns for osteoporosis therapies and fracture management solutions. In the Americas, demand is influenced by integrated healthcare delivery systems, payer-driven formulary processes, and growing emphasis on value-based contracts tied to outcomes such as fracture reduction and reduced hospital readmissions. These pressures encourage manufacturers to demonstrate real-world effectiveness and to partner with health systems on post-launch evidence generation and patient support programs.

In Europe, Middle East & Africa, regulatory harmonization, national procurement frameworks, and variable reimbursement environments create a mosaic of entry strategies. Country-level differences in pricing negotiation mechanisms and health technology assessment approaches require tailored market access planning and local evidence that addresses specific clinical and economic endpoints. The region also presents opportunities for centralized clinical collaborations and regional manufacturing investments that can improve supply security.

Asia-Pacific markets present diverse trajectories ranging from rapidly expanding access to advanced biologics in high-income urban centers to growing primary care capacity in emerging markets. Local regulatory pathways, rising clinical trial activity, and increasing investment in diagnostic infrastructure are shaping faster adoption of innovative agents in some markets, while in others cost and logistics remain significant barriers. Across all regions, cross-border collaboration on best-practice fracture liaison services and telehealth-enabled monitoring is becoming a differentiator in achieving better patient outcomes and broader therapy penetration.

Competitive strategies centered on biologic innovation, lifecycle management, partnerships, and integrated service offerings that shape product trajectories

Company strategies in the osteoporosis and fracture healing domain reveal a spectrum of approaches, from portfolio diversification and biologic innovation to lifecycle management and service integration. Some leading innovators concentrate on advancing monoclonal antibody and anabolic platforms, leveraging differentiated clinical profiles to secure premium formulary positions and specialist uptake. These organizations invest heavily in long-term safety monitoring, head-to-head comparative trials, and large-scale observational studies to sustain clinician confidence and to inform guideline inclusion.

At the same time, companies with established small-molecule portfolios prioritize cost-containment strategies, manufacturing optimization, and patient support services that improve adherence. Partnerships across diagnostic providers, homecare operators, and digital health firms are increasingly common as firms seek to offer bundled solutions that address the full continuum of fracture prevention and healing. Biosimilar entrants and contract manufacturers are influencing pricing dynamics and supply flexibility, which compels originator companies to accelerate innovation and to explore novel commercial models such as outcome-based pricing.

Across the competitive landscape, intellectual property management, regulatory lifecycle planning, and geographic diversification of manufacturing are recurrent themes. Firms that combine robust clinical evidence, resilient supply chains, and integrated service offerings are positioned to maintain competitiveness, while those that fail to adapt to evolving payer requirements or patient expectations risk erosion of uptake in key channels.

Actionable strategic initiatives emphasizing evidence generation, supply resilience, patient-centered delivery, and novel commercial models to secure competitive advantage

Industry leaders should adopt a coordinated set of strategic actions that align clinical differentiation with operational resilience and payer expectations. First, prioritize generation of real-world evidence and comparative effectiveness data that demonstrate both clinical benefit and systems-level value, enabling stronger negotiations with payers and inclusion in guideline-driven care pathways. Second, invest in supply chain diversification and incremental nearshoring to reduce exposure to tariff and trade disruptions, while ensuring that quality and regulatory compliance are preserved through robust supplier qualification processes.

Third, design patient-centric support programs and administration pathways that reconcile the convenience of oral agents with the adherence advantages of infrequent injectable regimens; incorporate telehealth, nursing support, and digital reminders to improve persistence. Fourth, pursue strategic collaborations with diagnostic providers and fracture liaison services to strengthen case-finding and secondary prevention workflows, thereby improving outcomes and reinforcing value-based contracting opportunities. Fifth, consider adaptive commercial models such as risk-sharing agreements and bundled payments for fracture care that align incentives across stakeholders.

Finally, embed regulatory and health technology assessment planning early in product development and life-cycle activities to expedite access and to address payer evidence requirements proactively. By aligning clinical, operational, and commercial priorities, leaders can convert emerging trends into sustainable competitive advantage.

An integrated, expert-validated research approach combining primary clinical and payer interviews with rigorous secondary evidence synthesis and scenario analysis

The research methodology underpinning this analysis integrates multi-source evidence, expert validation, and iterative triangulation to produce actionable insights. Primary research comprised structured interviews and advisory consultations with clinical specialists in endocrinology and orthopedics, hospital pharmacy directors, specialty clinic administrators, and payer and procurement representatives, providing direct perspectives on prescribing behavior, formulary decision-making, and care delivery constraints.

Secondary research included systematic review of regulatory approvals, peer-reviewed clinical literature, guideline statements, product labels, and publicly available safety communications to ensure alignment with the most recent clinical and regulatory developments. Real-world evidence sources such as health services utilization reports, clinical registries, and published outcomes research were examined to contextualize therapeutic performance and post-market experiences.

Data synthesis relied on cross-validation between primary insights and secondary datasets, with thematic coding used to identify recurrent opportunities and risks. Scenario analysis and sensitivity testing were employed to evaluate the operational impact of supply chain and trade policy changes. Throughout the research process, quality assurance protocols ensured source traceability and consistency, and subject-matter experts reviewed draft findings to confirm clinical plausibility and commercial relevance.

Summative insights that link therapeutic innovation, delivery transformation, and operational resilience into a clear pathway for sustained impact in fracture prevention and healing

In conclusion, the anti-osteoporosis therapy and fracture healing landscape is at an inflection point driven by therapeutic innovation, evolving care delivery models, and emerging supply chain and trade policy considerations. The ascent of anabolic and monoclonal antibody therapies is redefining clinical decision-making, while adherence and route-of-administration dynamics continue to influence real-world effectiveness. Meanwhile, tariff-induced supply chain considerations and growing payer emphasis on outcomes are reshaping commercialization tactics and operational planning.

Stakeholders who proactively integrate robust evidence generation, flexible manufacturing and sourcing strategies, and patient-centered delivery models will be better positioned to navigate this complex environment. Cross-sector collaborations that link diagnostics, digital health, and care coordination services have the potential to improve case-finding and reduce downstream fracture burden. Ultimately, the organizations that align scientific differentiation with demonstrable health-system value and resilient operations will capture durable opportunities in both established and emerging markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancement of romosozumab therapy under scrutiny for cardiovascular safety in high-risk osteoporosis patients
  • 5.2. Integration of wearable sensors and AI algorithms to monitor bone healing progression in real time
  • 5.3. Emerging use of gene therapy approaches targeting osteoblast activity to accelerate fracture repair in osteoporosis sufferers
  • 5.4. Development of novel sclerostin inhibitors with improved efficacy and reduced off-target adverse events in bone regeneration
  • 5.5. Increasing adoption of combination regimens of monoclonal antibodies and bisphosphonates for severe osteoporosis management
  • 5.6. Expansion of home-based telehealth platforms for remote monitoring of bone density and fracture healing outcomes
  • 5.7. Regulatory approvals of anabolic agents for long-term osteoporosis treatment shaping market access strategies
  • 5.8. Investigating the impact of gut microbiome modulation on bone density improvement and fracture risk reduction

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Osteoporosis Therapy & Fracture Healing Market, by Therapy Type

  • 8.1. Bisphosphonates
    • 8.1.1. Alendronate
    • 8.1.2. Ibandronate
    • 8.1.3. Risedronate
    • 8.1.4. Zoledronic Acid
  • 8.2. Hormone Replacement Therapy
    • 8.2.1. Combined Hormone Therapy
    • 8.2.2. Estrogen Therapy
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Denosumab
      • 8.3.1.1. Prolia
      • 8.3.1.2. Xgeva
    • 8.3.2. Romosozumab
  • 8.4. Parathyroid Hormone Analogues
    • 8.4.1. Abaloparatide
    • 8.4.2. Teriparatide
  • 8.5. Selective Estrogen Receptor Modulators
    • 8.5.1. Bazedoxifene
    • 8.5.2. Raloxifene

9. Anti-Osteoporosis Therapy & Fracture Healing Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Oral

10. Anti-Osteoporosis Therapy & Fracture Healing Market, by End User

  • 10.1. Homecare
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Anti-Osteoporosis Therapy & Fracture Healing Market, by Fracture Type

  • 11.1. Hip
  • 11.2. Spinal
  • 11.3. Wrist

12. Anti-Osteoporosis Therapy & Fracture Healing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anti-Osteoporosis Therapy & Fracture Healing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anti-Osteoporosis Therapy & Fracture Healing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Amgen Inc.
    • 15.3.2. Stryker Corporation
    • 15.3.3. Medtronic plc
    • 15.3.4. Novartis AG
    • 15.3.5. Merck & Co., Inc.
    • 15.3.6. Teva Pharmaceutical Industries Ltd.
    • 15.3.7. Eli Lilly and Company
    • 15.3.8. Orthofix Medical Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD